Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinbei oral liquid is a Traditional Chinese Medicine (TCM) formulation developed by Shandong Provincial Hospital for the treatment of idiopathic pulmonary fibrosis (IPF). As a botanical-based therapy, it is hypothesized to exert multi-target effects, including the inhibition of inflammatory responses and the modulation of pro-fibrotic signaling pathways, thereby reducing lung tissue scarring and improving respiratory function. It is typically administered as an oral solution and has been evaluated in multicenter, randomized, double-blind clinical trials to establish its efficacy and safety profile as a therapeutic option for patients with IPF.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jinbei oral liquid.